Figure S3 from Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the Tumor
Year: 2024
Type: other
Abstract: Supplemental Figure 3: Presence of canakinumab does not interfere with the ability to detect IL-1b in patient serum. Baseline serum from three randomly selected patients with pancreatic ductal adenocarcinoma was evaluated by cytokine bead array for IL-1b. For each patient sample, canakinumab was spiked in at the indicated concentrations. Note that measured IL-1b values were consistent across all samples from the same patient, regardless of the presence of canakinumab.
Authors: Paul E. Oberstein, Andressa Dias Costa, Emily A. Kawaler, Victoire Cardot-Ruffino, Osama E. Rahma, Nina Beri, Harshabad Singh, Thomas A. Abrams, Leah H. Biller, James M. Cleary, Peter Enzinger, Brandon M. Huffman, Nadine J. McCleary, Kimberly J. Perez, Douglas A. Rubinson, Benjamin L. Schlechter, Rishi Surana, Matthew B. Yurgelun, S. Jennifer Wang, Joshua Remland, Lauren K. Brais, Naima Bollenrucher, Eugena Chang, Lestat R. Ali, Patrick J. Lenehan, Igor Dolgalev, Gregor Werba, Cibelle Lima, C. Elizabeth Keheler, Keri M. Sullivan, Michael Dougan, Cristina Hajdu, Maya Dajee, Marc R. Pelletier, Saloney Nazeer, Matthew Squires, Dafna Bar-Sagi, Brian M. Wolpin, Jonathan A. Nowak, Diane M. Simeone, Stephanie K. Dougan
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4402201020